Parkman Healthcare Partners’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

Parkman Healthcare Partners’s Portfolio SURF Stock Details SURF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-115,577	Closed	-$190K	–	99
2022 Q2	$190K	Sell	115,577 -93,571	-45%	-$194K	0.07%	76
2022 Q1	$615K	Sell	209,148 -49,754	-19%	-$174K	0.18%	74
2021 Q4	$1.24M	Buy	258,902 +10,635	+4%	+$68.6K	0.27%	71
2021 Q3	$1.88M	Buy	248,267 +20,000	+9%	+$128K	0.48%	56
2021 Q2	$1.7M	Sell	228,267 -23,977	-10%	-$185K	0.37%	65
2021 Q1	$1.97M	Buy	252,244 +76,452	+43%	+$764K	0.46%	56
2020 Q4	$1.62M	Sell	175,792 -24,227	-12%	-$211K	0.42%	62
2020 Q3	$1.38M	Buy	200,019 +75,019	+60%	+$455K	0.37%	67
2020 Q2	$820K	Buy	+125,000	New	+$451K	0.23%	74

Other funds holding SURF

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Parkman Healthcare Partners's SURF Position: Q3 2022 in Review

Parkman Healthcare Partners sold out of Surface Oncology, Inc. Common Stock (SURF) in Q3 2022, closing a stake of 115,577 shares — an estimated $190K sold.

Parkman Healthcare Partners first reported a position in SURF in Q2 2020 and held it in 9 quarters. The position peaked at $1.97M in Q1 2021. 79 funds tracked by Wall St. Rank hold SURF as of Q3 2022.

Parkman Healthcare Partners reported no remaining Surface Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Parkman Healthcare Partners sold 115,577 Surface Oncology, Inc. Common Stock shares in Q3 2022, an estimated $190K.
Parkman Healthcare Partners first reported a position in Surface Oncology, Inc. Common Stock in Q2 2020 and held it in 9 quarters.
Parkman Healthcare Partners's Surface Oncology, Inc. Common Stock position peaked at $1.97M in Q1 2021.
79 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q3 2022.

Based on Parkman Healthcare Partners's 13F filing for Q3 2022, filed 14 Nov 2022.